BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. My time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to complete my PhD in molecular and cellular biology at the Rowett Research Institute. I joined the University of Aberdeen in 1996 as a post-doctoral scientist studying tumour biology and mechanisms of chemoresistance under Dr Howard Macleod and Professor Jim Cassidy. In 2014, I was appointed to establish and lead development of the Centre for Genome Enabled Biology and Medicine (CGEBM), a centre for genomics and bioinformatics at the University of Aberdeen. I continue to lead CGEBM and in 2024 I was appointed as Strategic lead for the Institute of Medical Sciences Facilities Centre at the University of Aberdeen to head the strategic direction, innovation and operational evolution of cytometry, genomics, histology, microscopy and proteomics. I have a research focus in tumour biology with a particular interest in breast cancer.
The technology hubs within the Institute of Medical Sciences Facilities Centre provide specialist expertise, infrastructure, training and a hub for methodological innovation, collaborative and interdisciplinary research design and information exchange, and bespoke research goal-oriented support in bioinformatics, cytometry, genomics, histology, microscopy and proteomics. This incorporates integrated application across technological fields in an era of multi-omics and sophisticated cellular and molecular resolution to drive understanding across diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen and beyond and addressing global challenges in human health and disease, agriculture and the environment.
Memberships and Affiliations
- Internal Memberships
-
University of Aberdeen
Aberdeen Grants Academy: Institutional Capital Equipment panel member
Research Facilities Working Group member
Research and Innovation Committee member, Institute of Medical Sciences
- External Memberships
-
2024 - Breast Cancer Now Prevention and Cure Grants Committee member.
2009 - 2014 Scientific Member, Experimental and Translational Medicine Research Committee, Chief Scientist Office.
2005 - 2009 Scientific Member, Biomedical and Therapeutics Research Committee, Chief Scientist Office.
Professional memberships
Genetics Society
British Association of Cancer Research
European Association of Cancer Research
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
I am course co-ordinator and teach MB5522 Advanced Bioinformatics and Genome Sequencing. I teach level 5 MB5021 Bioinformatics, MB5029 Toxicology and MT5515 Basic Research Methods; level 4 PA4303 Current Topics in Pharmacological research; level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and provide research project supervision to level 5 MSc students and BSc Honours students in the fields of cancer biology and genomics.
- Publications
-
Page 4 of 7 Results 31 to 40 of 66
Cancer Therapy Prognosis and Target
Patents: PatentsPregnane X Receptor Activators Inhibit Human Hepatic Stellate Cell Trans-Differentiation in Vitro
Gastroenterology, vol. 131, no. 1, pp. 194-209Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1053/j.gastro.2006.04.012
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
Journal of Clinical Oncology, vol. 24, no. 11, pp. 1729-1744Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1200/JCO.2005.03.3399
The Rectal Adenocarcinoma Transcriptome Reveals a Novel Prognostic Biomarker and Candidate Novel Targets for Neoadjuvant Therapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1)
Colorectal Disease, vol. 8, no. S2Contributions to Journals: ArticlesGene expression profiling of clinical response in rectal adenocarcinomas reveals novel predictive biomarkers and therapeutic targets.
Contributions to Conferences: AbstractsGlobal gene expression profiling of clinical response to radiotherapy and chemoradiotherapy in rectal adenocarcinoma reveals distinct and common molecular mechanisms of action.
Contributions to Conferences: AbstractsIdentification of the lysosomal programmed cell death (PCD) pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer, vol. 49, no. S141-142Contributions to Journals: ArticlesPutative Novel Mechanisms Of Tomudex Resistance And Insight Into TS-Independent 5-Flurouracil Resistance Networks.
Contributions to Conferences: AbstractsRectal adenocarcinoma transcriptome profiles reveal distinct molecular effects of radiotherapy and chemoradiotherapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1).
Contributions to Conferences: AbstractsRole of CD200 in tolerance induction: gene expression profiling of lymphoid tissues in response to intranasal antigen.
Immunology, vol. 116, no. 13Contributions to Journals: Articles